ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.54
-0.09%
US Tech 100
19,220.00
-0.20%
S&P 500
5,464.62
-0.16%
US Dollar vs CAD
1.36945
-0.04%
Bitcoin
64,085.74
-0.25%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sciele Pharma (MM) (SCRX)

  7. Sciele Pharma (MM) (SCRX) News

SCRX

Sciele Pharma (MM) (SCRX)

Sciele Pharma (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SCRX
DateTimeSourceHeadlineSymbolCompany
08/25/202112:00PMBusiness WiretheScore Bet Becomes Official Gaming Partner of Golf Canada and its Marquee Golf Championships, the RBC Canadian Open and CP Women’s OpenNASDAQ:SCRXSciele Pharma (MM)
08/19/20219:00AMBusiness WiretheScore Selects Toronto’s Waterfront Innovation Centre as Site for New, Expansive HeadquartersNASDAQ:SCRXSciele Pharma (MM)
08/05/20216:01AMBusiness WirePenn National Gaming to Acquire Score Media and Gaming, Creating North America’s Leading Digital Sports Content, Gaming and Technology CompanyNASDAQ:SCRXSciele Pharma (MM)
07/13/20214:01PMBusiness WiretheScore Reports F2021 Q3 Financial ResultsNASDAQ:SCRXSciele Pharma (MM)
07/06/20216:30AMBusiness WiretheScore to Report Q3 F2021 Financial Results on Tuesday, July 13, 2021NASDAQ:SCRXSciele Pharma (MM)
06/22/20213:16PMBusiness WiretheScore Applauds Passage by the Senate of Historic Legislation to Legalize Single Event Sports Betting in CanadaNASDAQ:SCRXSciele Pharma (MM)
04/22/20216:41PMBusiness WiretheScore Issues Statement Following the Passing of Bill C-218 by the House of CommonsNASDAQ:SCRXSciele Pharma (MM)
04/13/20214:02PMBusiness WiretheScore Reports Record F2021 Q2 Financial ResultsNASDAQ:SCRXSciele Pharma (MM)
04/06/20216:45AMBusiness WiretheScore To Report Q2 F2021 Financial Results on Tuesday, April 13, 2021NASDAQ:SCRXSciele Pharma (MM)
03/30/202112:02PMBusiness WirePGA TOUR Announces theScore Bet as an Official Betting OperatorNASDAQ:SCRXSciele Pharma (MM)
03/29/20217:30AMBusiness WiretheScore Secures Market Access for Mobile Sports Betting in Illinois Through Agreement with Caesars EntertainmentNASDAQ:SCRXSciele Pharma (MM)
03/01/202110:04AMBusiness WiretheScore Announces Closing of US$186.3 Million Initial Public Offering in the United StatesNASDAQ:SCRXSciele Pharma (MM)
10/09/20084:01PMBusiness WireShionogi Completes Acquisition of ScieleNASDAQ:SCRXSciele Pharma (MM)
10/09/200810:10AMEdgar (US Regulatory)Amended Statement of Ownership: Solicitation (SC 14D9/A)NASDAQ:SCRXSciele Pharma (MM)
10/09/20087:02AMEdgar (US Regulatory)Amended tender offer statement by Third Party (SC TO-T/A)NASDAQ:SCRXSciele Pharma (MM)
10/09/20086:30AMBusiness WireShionogi and Sciele Announce Completion of Subsequent Offering PeriodNASDAQ:SCRXSciele Pharma (MM)
10/06/20088:54AMEdgar (US Regulatory)Sciele Pharma, Inc. - Amended Statement of Ownership: Solicitation (SC 14D9/A)NASDAQ:SCRXSciele Pharma (MM)
10/06/20085:30AMBusiness WireShionogi and Sciele Announce Successful Tender Offer and Commencement of Subsequent OfferingNASDAQ:SCRXSciele Pharma (MM)
10/06/20085:05AMEdgar (US Regulatory)Sciele Pharma, Inc. - Amended tender offer statement by Third Party (SC TO-T/A)NASDAQ:SCRXSciele Pharma (MM)
10/01/20088:45AMEdgar (US Regulatory)Sciele Pharma, Inc. - Amended tender offer statement by Third Party (SC TO-T/A)NASDAQ:SCRXSciele Pharma (MM)
09/25/20086:38PMPR Newswire (US)Standard & Poor's Announces Update to the U.S. Market Cap Guidelines and Changes to U.S. IndicesNASDAQ:SCRXSciele Pharma (MM)
09/19/20088:44AMEdgar (US Regulatory)Sciele Pharma, Inc. - Amended Statement of Ownership: Solicitation (SC 14D9/A)NASDAQ:SCRXSciele Pharma (MM)
09/19/20085:08AMEdgar (US Regulatory)Sciele Pharma, Inc. - Amended tender offer statement by Third Party (SC TO-T/A)NASDAQ:SCRXSciele Pharma (MM)
09/19/20085:00AMBusiness WireShionogi and Sciele Announce Receipt of United States Antitrust ClearanceNASDAQ:SCRXSciele Pharma (MM)
09/16/20088:46AMBusiness WireSciele Completes Pivotal Phase III Program for Glycopyrrolate in Pediatric Patients with Chronic, Moderate-to-Severe DroolingNASDAQ:SCRXSciele Pharma (MM)
09/08/200810:19AMEdgar (US Regulatory)Sciele Pharma, Inc. - Statement of Ownership: Solicitation (SC 14D9)NASDAQ:SCRXSciele Pharma (MM)
09/08/200810:03AMEdgar (US Regulatory)Sciele Pharma, Inc. - Tender offer statement by Third Party (SC TO-T)NASDAQ:SCRXSciele Pharma (MM)
09/03/20083:49PMEdgar (US Regulatory)Sciele Pharma, Inc. - Written communication by the subject company relating to a third party tender offer (SC14D9C)NASDAQ:SCRXSciele Pharma (MM)
09/03/20083:47PMEdgar (US Regulatory)Sciele Pharma, Inc. - Current report filing (8-K)NASDAQ:SCRXSciele Pharma (MM)
09/02/20083:58PMEdgar (US Regulatory)Sciele Pharma, Inc. - Statement of Ownership: Solicitation (SC 14D9)NASDAQ:SCRXSciele Pharma (MM)
 Showing the most relevant articles for your search:NASDAQ:SCRX

Your Recent History

TG
GBQ
Gbk Beteilig Ag O N
TG
NA9
Nagarro
EU
MLCAC
Lombard Et Medot
NYSE
MD
Pediatrix Medical
NYSE
SXC.WI
TG
BB62
Bundesanleihe von
GATE
NASUSDT
Nebulas
EU
CARAD
Carmila 1.89% until 06no...
ASX
CVE
NASDAQ
ABAGQXX
Royal Bank of Canada Unc...
NASDAQI
SX4520GI
OMX Stockholm Personal C...
DOWI
DWMFUT
DJ Middle East & Africa ...
EU
XS2696829816
ABN Amro Bank NV Aabfrn2...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved